The molecular taxonomy of primary prostate cancer

By Adam Abeshouse, Jaeil Ahn, Rehan Akbani, Adrian Ally, S. Amin, C. Andry, Matti Annala, A. Aprikian, J. Armenia, Arshi Arora and 300 more. Cell, 2015

2,751 citations recorded by the source corpus.

Summary There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, FLI1) or mutations (SPOP, FOXA1, IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1-mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bbb5dce4804a2da1710cbd30d89d102b6b55ab69

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Peter W. Laird
2. M. Lawrence
3. M. Wiznerowicz
4. Houtan Noushmehr

Citations in the corpus

• Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer (2018, background): “…of stemness, attesting to their underlying molecular heterogeneity, as previously reported (Cancer Genome Atlas Network, 2015; Cancer Genome Atlas Research Network, 2011, 2012, 2014a, 2014b, 2015a, 2015b, 2017; Cancer Genome Atlas Research Network et al., 2013a, 2013b; Robertson et al., 2017).”